Interindividual variability in genes encoding drug-metabolizing enzymes, transporters,
receptors, and human leukocyte antigens has a major impact on a patient's response to …

The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Genetic medicine is one of the key components of personalized medicine, but adoption in
clinical practice is still limited. To understand potential barriers and provider attitudes, we …

The limitations of traditional two-dimensional (2D) cultures and animal testing, when it
comes to precisely foreseeing the toxicity and clinical effectiveness of potential drug …

Pharmacogenomics can enhance patient care by enabling treatments tailored to genetic
make-up and lowering risk of serious adverse events. As of June 2019, there are 132 …

In psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-
and-error approach. The prescribing of these medications is complicated by sub-optimal …

Clinical decision support (CDS) is an essential part of any pharmacogenomics (PGx)
implementation. Increasingly, institutions have implemented CDS tools in the clinical setting …

Background Cardiovascular diseases and especially Acute Coronary Syndrome (ACS)
constitute a major health issue impacting millions of patients worldwide. Being a leading …

Genomic healthcare programmes, both in a research and clinical context, have
demonstrated a pivotal opportunity to prevent, diagnose, and treat rare diseases. However …

Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among
healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx …